Cdk5, a member of the cyclin-dependent kinase family, has been shown to play an important role in development of the central nervous system in mammals when partnered by its activator p35. Here we describe the cloning and characterization of a novel activator of cdk5 in Xenopus, Xp35.2. Xp35.2 is expressed during development initially in the earliest differentiating primary neurons in the neural plate and then later in differentiating neural tissue of the brain. This is in contrast to the previously described Xenopus cdk5 activator Xp35.1 which is expressed over the entire expanse of the neural plate in both proliferating and differentiating cells. Expression of both Xp35.1 and Xp35.2 and activation of cdk5 kinase occur when terminal neural differentiation is induced by neurogenin and neuro D overexpression but not when only early stages of neural differentiation are induced by noggin. Moreover, blocking cdk5 kinase activity specifically results in disruption and reduction of the embryonic eye where cdk5 and its Xp35 activators are expressed. Thus, cdk5/p35 complexes function in aspects of neural differentiation and patterning in the early embryo and particularly in formation of the eye.
INTRODUCTION
Cdk 5 was originally identified as a well-conserved member of the cyclin-dependent kinase family of proteins (Meyerson et al., 1992) . The prototypical cdks play pivotal roles in regulating cell cycle transitions when bound to their specific activators, the cyclins. In contrast, mammalian cdk5 is expressed predominantly in postmitotic cell populations where it is found complexed not to cyclins but to members of a new class of activator, typified by the protein p35 (Ishiguro et al., 1994; Lew et al., 1994; Tsai et al., 1994) . p35 itself is expressed predominantly in postmitotic neurons of the central nervous system and its presence correlates well with demonstrated cdk5 kinase activity (Lew et al., 1994; Tsai et al., 1994; Zheng et al., 1998) .
The expression pattern of active cdk5, found in postmitotic cells particularly in the central nervous system, is indicative of an important function in neural differentiation or patterning. This role was confirmed by demonstrating that neurons in primary cortical cultures which were transfected with a dominant negative cdk5 construct had a specifically reduced propensity to elaborate neurites (Nikolic et al., 1996) . In contrast, neurons expressing increased levels of cdk5 and p35 showed enhanced neurite outgrowth. More recently a cdk5 null mouse has been reported which exhibits perinatal lethality with extensive defects in the central nervous system including lack of stratification in the neocortex and lack of foliation in the cerebellum (Ohshima et al., 1996) . A p35 null mouse has also been generated which displays a more subtle phenotype; while adults are viable and fertile they suffer from seizures (Chae et al., 1997) . Microscopic examination reveals disruption of the cortical laminar structure due to failure of the newly differentiated neurons to migrate past older neurons to take up their more usual superficial position, as well as a number of additional subtle neural defects. The cdk5 null mouse has a more severe phenotype than that of the p35 null mouse, raising the possibility of the existence of other activating partners. Indeed, another p35 family member, p39, has been identified which has an expression pattern in the central nervous system distinct from that of p35 (Tang et al., 1995; Zheng et al., 1998) .
While it is clear that cdk5/p35 plays an important role in neurogenesis in the early embryo, the limitations of the mouse for studying early embryonic stages makes it difficult to study the precise role of this complex in neural differentiation. To look at these early processes in more detail, we have turned to embryos of the frog Xenopus laevis. These have a number of advantages as an experimental system for studying early neurogenesis, most notably the large size of the embryos, the fact that they develop outside the mother, and the potential for use of explant culture systems to study neural differentiation in isolation from other patterning events.
Cdk5 has been cloned in Xenopus and it shows 97% amino acid homology to its rat counterpart (Gervasi and Szaro, 1995) , indicating a high potential for functional conservation. Xcdk5 is widely expressed throughout tissues of the early tadpole (Philpott et al., 1997) . We have cloned two p35 activators of cdk5 from Xenopus embryonic cDNA libraries. Surprisingly one, Xp35.1, is expressed in dividing cells of mesodermal and neural lineage early in development and later remains strongly expressed in the brain and the myotome (Philpott et al., 1997) . Blocking cdk5 kinase activity in the early embryo by microinjection of a dominant negative cdk5 construct results in disruption of myotomal muscle. Moreover, experiments investigating the induction of muscle in embryonic animal pole explants (animal caps) in response to the TGF-␤ family member activin demonstrate that cdk5 kinase activity is required for expression of myogenic genes and muscle markers that are turned on as differentiation of muscle progresses (Philpott et al., 1997) .
These studies demonstrated a new role for cdk5 in regulation of muscle differentiation but failed to address a role for this kinase in neurogenesis in the early Xenopus embryo. As described previously, Xp35.1 is expressed over the entire expanse of the neural plate in both proliferating and differentiating cells (Philpott et al., 1997) . In contrast, we have also cloned a p35 homologue in Xenopus, Xp35.2, described in this study, which is expressed solely in differentiating neurons. We find that cdk5 kinase is activated in animal pole explants which are induced to form terminally differentiated neurons and that this is accompanied by the increased expression of both Xp35.1 and Xp35.2, and cdk5. However, induction of only the early stages of neural differentiation, as induced by noggin, is not sufficient to activate cdk5 kinase. Blocking cdk5 kinase activity does not alter expression of markers of either early or late neural differentiation in the intact embryo or in explant culture indicating that cdk5 does not act at the level of expression of neural-specific genes. This contrasts with the demonstrated role of cdk5 in regulating expression of musclespecific genes (Philpott et al., 1997) . However, blocking cdk5 kinase activity in the embryo does result in specific reduction and disruption of the eye confirming an important role of cdk5/p35 in differentiation and patterning of this predominantly neural structure. Thus, cdk5 kinase may play an important role in terminal differentiation and patterning of embryonic neural structures in Xenopus but not in the specification of proneural domains.
MATERIALS AND METHODS

Library Screening
The library screening method used to isolate Xp35.2 (Fig. 1) is described in detail elsewhere (Philpott et al., 1997) .
H1 Kinase Assay
Embryos were left uninjected or injected with RNAs described. Two whole embryos were homogenized at stage 13 (Fig. 2 ) in 200 l IP buffer (Philpott et al., 1997) . Cdk5 was immunoprecipitated from cleared homogenates using the C-terminal C8 antibody (Santa Cruz) and these immunoprecipitates were tested for their ability to phosphorylate histone H1 exactly as described in Philpott et al. (1997) .
Extracts from animal caps (Figs. 5 and 7, 500, or 200 g total protein, respectively) were assayed for cdk5 kinase activity as described in Tsai et al. (1993) .
RT-PCR Analysis
RT-PCR analysis was performed as described previously (Lustig and Kirschner, 1995; Lustig et al., 1996; Philpott et al., 1997) . Novel primer sequences are provided. Xp35.2: forward, 5Ј-TCAAGCGGTGCCAGGGAG-3Ј; reverse, 5Ј-TCTGTTCCAG-TGGGGC-3Ј.
The primer sequences for neural ␤-tubulin and NCAM were taken from the Xenopus molecular marker resource on the World Wide Web (http://vize 222@zo.utexas.edu). Neural ␤-tubulin was amplified for 30 cycles and NCAM was amplified for 21 cycles. Xp35.2 was amplified for 30 cycles.
Embryos and Explants
Embryos were injected and animal caps cut and cultured as described in Philpott et al. (1997) . Caps were cultured until sibling embryos had reached stage 25 (Fig. 5 ) or stage 28 (Fig. 7) or as described in the figure legend to Fig. 6 .
In Situ Hybridization, Sectioning, and Staining
Whole-mount in situ hybridization was performed as described in Harland (1991) using digoxigenin-11-UTP-labeled probes (Boehringer). The antisense probe for full-length Xp35.2 was synthesized using T7 polymerase and a Bluescript vector. 4-Nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-indolyl-phosphate, 4-toluidine salt (BCIP) were used as substrates for the color reaction giving purple staining. Stained embryos were viewed in whole mount either uncleared (Figs. 4Ai and 4Aii, Fig. 8a ) or cleared with benzoyl benzoate:benzoic acid at 2:1 (Fig. 4Aiii) . Where appropriate, embryos were fixed in MEMFA overnight after staining, embedded in JB4 plastic resin, and sectioned (Fig. 4B) . Alternatively, stage 35/36 embryos (Fig. 8b) were fixed in MEMFA, embedded in Paraplast medium (Oxford Labware), sectioned sagi-tally, and then stained with hemotoxylin and eosin and mounted in Permount (Sigma). Detection of ␤-galactosidase activity was by the method of Vize et al. (1991) .
Constructs
Human cdk5 wild-type (WT) and cdk5 dominant negative (DN) (Meyerson et al., 1992; van den Heuvel and Harlow, 1993) including a C-terminal HA tag cloned into pCS2ϩ (Turner and Weintraub, 1994) are as described in Philpott et al. (1997) and were used throughout this study. Xp35.2 was cloned into the XhoI and XbaI sites of pCS2 MTϩ and used for in vitro transcription using SP6 polymerase. Xp35.1, neurogenin, neuro D, and noggin were expressed from CS2ϩ vectors using SP6 polymerase.
RESULTS
Cloning a New Kinase Activator of cdk5, Xp35.2
To identify homologues of human p35 we screened a stage 28 Xenopus embryo head library at low stringency with partial human p35 cDNA (Tsai et al., 1994) coding for the carboxy-terminal 600 bp (Philpott et al., 1997) . After screening 500,000 plaques, two positive clones were obtained. One of these coded for the partial reading frame of Xp35.1, described in detail by Philpott et al. (1997) . The second clone had a 2.5-kb insert which contained the full open reading frame for a protein of 293 amino acids with molecular weight 32.8 kDa which showed significant homology to human p35 across extensive portions of the molecule. Xp35.2 shows 79% amino acid identity with human p35 across its entire length. This compares with 68% identity between Xp35.1 and human p35. This indicates that Xp35.2 may be the true Xenopus homologue of human p35 and this conclusion is strengthened by the Xp35.2 localization pattern presented below. Xp35.2 is 64% identical to Xp35.1 and this similarity is found mainly in the highly conserved C-terminal cdk5 binding and activation domain (76% identity at the amino acid level).
To 
Xp35.2 Expression during Embryogenesis
We have used quantitative reverse-transcription PCR analysis to examine developmental expression of Xp35.2 transcripts using ornithine decarboxylase as a loading control. Xp35.2 is barely detectable before the midblastula transition and although levels rise somewhat after MBT, they remain relatively low until tailbud stages. (Slight fluctuations seen in early stages are not reproducible and probably reflect slight variations of detection of messages at these low levels.) At around stage 23 transcript levels increase dramatically and plateau soon afterward. Notably, many cell types including neurons are undergoing extensive differentiation at this time (Hartenstein, 1989; Jacobson and Huang, 1985) . Interestingly, Xp35.1 which is first expressed after MBT shows greater expression in earlier developmental stages when embryonic tissues are still proliferating but its expression rises more gradually than Xp35.2 during the later stages of tadpole development (Philpott et al., 1997) .
To determine the spatial expression of Xp35.2 during early embryogenesis we performed in situ hybridization analysis. In agreement with RT-PCR data, Xp35.2 was undetectable over background in blastula and gastrula embryos. However, by mid-neural plate stages Xp35.2 is clearly detected in two anterior regions that correspond to trigeminal placodes (Fig. 4Ai , labeled TG). In addition, Xp35.2 is expressed symmetrically in two stripes on either side of the midline in the neural plate. Staining is strongest in the more lateral stripes characteristic of expression in the primary motor neurons, the first neurons to exit from the cell cycle and differentiate (Hartenstein, 1989; Jacobson and Huang, 1985) . Expression is also detected in two medial stripes which correspond to primary sensory neurons. Xp35.2 is not clearly seen in the potential third stripe of primary interneurons, although such staining could be weak and obscured by background staining. In addition, staining of the stripe of primary sensory neurons is relatively wide, which may further obscure any interneuron staining. Figure 4Aii shows the dorsal view of an early tailbud-stage embryo. Again, Xp35.2 is present in two stripes symmetrically arranged with respect to the midline on either side of the closed neural tube indicative of staining in the primary neurons. Staining is also prominent in nerves leaving the neural tube to enter the otic vesicles (arrow) and nerves emerging from the trigeminal ganglia FIG. 2. Both Xp35.1 and Xp35.2 are able to activate cdk5 kinase activity. One nanogram RNA encoding myc-tagged Xp35.1 (lane 1) or Xp35.2 (lane 2) was injected into fertilized eggs. Uninjected embryos were used as controls (lane 3). At stage 13 extracts were produced from two injected embryos and cdk5 was specifically immunoprecipitated. These immunoprecipitates were tested for their ability to phosphorylate the model substrate histone H1.
FIG. 3.
Developmental expression of Xp35.2. Two micrograms of RNA from developmentally staged embryos was reverse transcribed in a 20-l reaction. One microliter per lane was used for quantitative RT-PCR analysis using primers specific for Xp35.2. Ornithine decarboxylase, expressed constantly through development, was also used as a loading control.
(data not shown). Figure 4Aiii shows a late tailbud-stage embryo which has been cleared to view Xp35.2 staining in the brain. In agreement with RT-PCR data, Xp35.2 expression has increased dramatically by this stage. Message remains throughout the entire length of the neural tube (data not shown) but is strongest anteriorly in the forebrain, midbrain, and hindbrain and in the cranial nerves. A conspicuous area of reduced staining at the back of the midbrain corresponds to the posterior tectum, a zone where cells are constantly being generated, and thus represents an area of reduced differentiation.
Thus, Xp35.2 is expressed exclusively in differentiating neurons in the Xenopus embryo. This expression of Xp35.2 is in contrast to that of the closely related Xp35.1 which is expressed over the entire expanse of the neural plate during earlier neurula stages when most cells in the region retain their proliferative capacity and which is expressed later throughout the closed neural tube (Philpott et al., 1997;  data not shown). Thus, it seems that Xp35.2 rather than Xp35.1 may be more analogous to mammalian p35 which is expressed exclusively in populations of differentiating neurons which have exited the cell cycle in the central nervous system (Lew et al., 1994; Tsai et al., 1994) . Figure 4B shows Xp35.2 expression in a cross-section of the head of a tailbud-stage embryo. Strong expression in the primary differentiating neurons is visible in outer layers of the forebrain (thin arrows) while Xp35.2 is also strongly expressed in the retina (thick arrow). Staining is strongest on the vitreal surface of the retina where ganglion cells are differentiating. These ganglion cells are the first cells to
FIG. 4.
Xp35.2 is specifically expressed in differentiating neural tissue. Albino embryos were used for in situ hybridization analysis using a digoxigenin-labeled Xp35.2 antisense probe, visualized in purple against a white/pink background. Embryonic stages are (Ai) dorsal view of neural plate stage, (Aii) dorsal view of early tailbud, and (Aiii) lateral view of the head of a late tailbud-staged embryo. Staining of the trigeminal ganglion (TG) is highlighted with an arrow. (B) A section through the head of a stage 35/36 embryo where Xp35.2 expression has been detected by whole-mount in situ hybridization and then the embryo has been sectioned. Xp35.2 staining is strong in differentiating neurons of the forebrain (thick arrow) and ganglion cells of the retina (thin arrows). differentiate in the embryonic eye (Holt et al., 1988) . We have also seen that Xp35.1 is strongly expressed in the lens (Philpott et al., 1997 ; data not shown), while cdk5 is expressed throughout the eye (Philpott et al., 1997) . This raises the possibility that cdk5, partnered by both Xp35.1 and Xp35.2, could play a role in development and differentiation of a number of tissues in the embryonic eye (see below). Cdk5, p35, and p39 are all strongly expressed in neural components of the embryonic eye of the rat as well as in the lens (Zheng, 1998, #41; Gao et al., 1997) .
Neural Inducers Can Activate cdk5
We have shown previously that cdk5 kinase is activated in animal caps induced to form mesoderm by the TGF-␤ family member activin but not in animal caps which have followed the default pathway of epidermal differentiation (Philpott et al., 1997) . We wished to determine whether inducers of neural commitment and differentiation would also induce cdk5 kinase activity using this animal cap explant system. To induce formation of neural tissue in animal caps we have used noggin, an extracellular inhibitor of the BMP signaling pathway which induces animal caps to enter down a proposed default pathway of neural induction (Zimmerman et al., 1996) . In addition, we have used ectopic expression of the neurogenic genes neurogenin and neuro D which act to induce the formation of neural tissue directly by activating transcription of neuralizing genes Ma et al., 1996) . In contrast to the relatively undifferentiated neural tissue induced by overexpression of noggin, neurogenin and neuro D overexpression results in the formation of neural tissue containing discrete neurons that display many characteristics of terminal differentiation.
Fertilized Xenopus eggs were either left untreated or injected with RNA coding for neurogenin, neuro D, or noggin. At stage 8.5-9 animal caps were cut and cultured while a sample of uninjected caps was incubated in activin at 2 ng/ml. Animal caps were collected when parallel embryos had reached stage 25 and RNA from six caps was reverse transcribed into cDNA for RT-PCR analysis. Protein extracts were prepared from the remaining caps, the endogenous cdk5 immunoprecipitated, and kinase activity measured by the ability of the immunoprecipitate to phosphorylate the model substrate histone H1.
Figure 5, lane 1 shows that untreated animal caps that have followed the default pathway to epidermal differentiation have low levels of cdk5 kinase activity. In contrast, caps that have been induced to form differentiating neurons by injection of neurogenin and neuro D show seven-and fourfold enhancement of cdk5 kinase activity, respectively (Fig. 5, lanes 2 and 3) . In marked contrast to neurogenin and neuro D which induce terminal neural differentiation, noggin, which induces only the early stages of neural commitment and differentiation (Lamb et al., 1993) , is unable to induce the activation of cdk5 kinase (lane 4). Activin treatment also activates cdk5 as described previously (Philpott et al., 1997) , although this enhancement is modest compared to that seen with neurogenin and neuro D (lane 6). Thus, we demonstrate that neurogenin and neuro D, but not noggin, are able to activate cdk5 kinase activity. This does not reflect an inability of noggin to induce at least the early stages of neural differentiation. Figure 5B shows the result of RT-PCR analysis of animal caps from embryos injected with noggin, neurogenin, and neuro D RNA. All 4) or with (lane 5) activin at 2 ng/ml. Animal caps were aged until parallel embryos had reached stage 25 and whole embryos at this stage were also taken as a control (lane 6). Protein extracts were prepared and cdk5 was then specifically immunoprecipitated. Immunoprecipitates were tested for their ability to phosphorylate the model substrate histone H1. (B) Alternatively, six animal caps produced and aged until stage 25 exactly as described above were used for RT-PCR analysis to determine the expression of the pan-neural marker NCAM and the ubiquitously expressed EF1␣ message which is used as a loading control. Uninjected embryo (lane 1) or embryos injected with RNA encoding neurogenin (50 pg, lane 2), neuro D RNA, (500 pg, lane 3), or noggin (25 pg, lane 4).
three genes are able to induce robust expression of the early neural marker NCAM.
Induction of cdk5 and Activators by Neuralizing Genes
We wished to determine whether neurogenin and neuro D activated cdk5 kinase activity in this animal cap assay by inducing the expression of cdk5 and/or its activators Xp35.1 and Xp35.2. In a similar experiment to that described in the legend to Fig. 5 , we injected fertilized eggs with RNA encoding neurogenin, neuro D, and noggin. Animal caps were cut at stage 8.5 and harvested at stage 13, stage 19, and stage 26 (as labeled in Fig. 6 ). Isolated RNA was reverse transcribed into cDNA and quantitative RT-PCR analysis was performed to determine the expression level of cdk5, Xp35.1, and Xp35.2 as well as that of the neural markers neural ␤-tubulin and NCAM. EF1␣ expression was used as a loading control. Signals were quantitated by phosphoimage analysis to give an approximation of fold induction of gene expression over that seen in the uninjected control caps.
Xp35.1, Xp35.2, and cdk5 were expressed at low but detectable and constant levels in uninjected animal caps at all three stages indicating that, as expected, these genes are not specifically induced on epidermal differentiation. Both neurogenin and neuro D give strong induction of neural ␤-tubulin even by stage 13 (both approximately 30-fold over uninjected controls), rising further during development. Neurogenin and neuro D overexpression resulted in a similar level of neural gene induction and had a similar effect on Xp35.1, Xp35.2, and cdk5 expression. Both neuro D and neurogenin enhance expression of cdk5 only significantly by stage 26 (approximately 10-to 12-fold, respectively). However, their effect on Xp35.1 and Xp35.2 can even be seen as early as stage 13 where Xp35.1 expression is increased 2-fold by neurogenin while Xp35.2 RNA level is enhanced 6-fold by both neurogenin and neuro D. By stage 26, Xp35.1 is more than 2.5 times more highly expressed in neurogenin-and neuro D-injected caps than the uninjected controls. More dramatically, by stage 26 Xp35.2 expression levels increase by approximately 15-fold over the uninjected control in the presence of neurogenin and neuro D.
Noggin injection induced robust expression of NCAM in animal caps even by stage 13 that remained constant until stage 26. Interestingly, under these conditions, and in contrast to previous reports (Ferreiro et al., 1994; Lamb et al., 1993; Papalopulu and Kintner, 1996) , noggin did induce a low level of neural tubulin expression even by stage 13 (approximately 2-fold) and by stage 26 this was as much as 30-fold increased, although neural ␤-tubulin expression was always considerably lower than that seen with neurogenin or neuro D. The enhancement of neural ␤-tubulin by noggin, especially at later times seen here, may reflect the comparatively lengthy aging of animal caps in this experiment (Lamb and Harland, 1995; Papalopulu and Kintner, 1996) . However, even given this increase in ␤-tubulin expression induced by noggin, cdk5, Xp35.1, and Xp35.2 levels are completely unaffected.
Thus, neurogenin and neuro D induce cdk5 kinase activity probably via the increased expression of cdk5 itself as well as its activating partners Xp35.1 and Xp35.2. It is interesting to note that these neurogenic genes induce the expression of Xp35.2 more strongly than Xp35.1, and Xp35.2 in contrast to Xp35.1 is found exclusively in differentiating neurons. In contrast, Xp35.1 and Xp35.2 expression is not induced by noggin which has limited ability to induce terminal differentiation of neurons.
Cdk5 Kinase Activity Is Not Required for Neural Gene Expression
Cdk5 has been shown to have a largely cytoplasmic function in mammalian neurons (Nikolic et al., 1996; Tsai et al., 1993) where it has a potential role in cytoskeletal regulation during axonal outgrowth phosphorylating sub- strates such as tau and MAP 2 (Lew and Wang, 1995) . However, we have demonstrated that cdk5 kinase in Xenopus embryos functions to regulate the expression of myogenic genes; expression of the cdk5 dominant negative mutant in animal caps downregulates expression of the myogenic genes Myo Db and MRF 4 as well as the muscle marker muscle actin (Philpott et al., 1997) . In Fig. 6 we have demonstrated that neurogenin and neuro D are able to induce the expression of both cdk5 and its Xp35 partners as well as markers of early and late neural differentiation. Therefore, it is possible that these neurogenic genes require cdk5 kinase activity to upregulate neural gene expression by analogy to the requirement for cdk5 kinase activity to activate muscle gene expression in Xenopus. To address this question, we have used a mutant of cdk5 which can bind p35 activators but is kinase inactive and thus acts as a dominant negative when injected into Xenopus embryos (Nikolic et al., 1996) . This was used to demonstrate a requirement for cdk5 kinase in muscle differentiation (Philpott et al., 1997) . Embryos were injected either with neurogenin or neuro D alone or in combination with RNA encoding cdk5 or cdk5 dominant negative (cdk5 DN). Animal caps were cut from these embryos at stage 8.5 and aged until parallel embryos had reached stage 28. RNAs were prepared from these animal caps, reverse transcribed into cDNAs, and then used as templates for quantitative RT-PCR analysis to detect NCAM and neural ␤-tubulin expression, markers of early and late neural differentiation, respectively. Animal caps cut from uninjected embryos (Fig. 7A , lane 1) expressed virtually no NCAM or ␤-tubulin. In contrast, both neurogenin and neuro D induced robust levels of expression of both markers (lanes 2 and 5). Injection of either wild-type (lanes 3 and 6) or dominant negative (lanes 4 and 7) cdk5 had no significant effect on expression levels of NCAM or ␤-tubulin.
The injected cdk5 DN is working efficiently to block endogenous cdk5 kinase activity in this assay. Figure 7B shows cdk5 kinase activity of cdk5 immunoprecipitates from extracts of uninjected animal caps (lane 1), animal caps injected with neurogenin (lane 2), or animal caps injected with neurogenin and cdk5 DN (lane 3). As expected, ectopic neurogenin expression leads to activation of cdk5 kinase even in stage 28 caps and this can be efficiently blocked by coinjection of cdk5 DN. Thus, cdk5 does not appear to play a role in regulating neurogenin-or neuro D-mediated control of neural gene expression.
Cdk5 Kinase Activity Is Required for Normal Eye Formation in the Xenopus Embryo
We have shown previously that cdk5 kinase activity is required for normal development and patterning of the myotome in early embryos. In addition, we saw that embryos expressing cdk5 DN clearly showed some disruption of head neural structures, particularly the eye (Philpott et al., 1997 ; data not shown). We wished to investigate more closely the effect of blocking cdk5 kinase activity on development of neural structures in the early embryo. A total of 2.5 ng of either cdk5 WT or cdk5 DN RNA was injected into one dorsal cell of a four-cell embryo in the animal hemisphere, along with 0.5 ng ␤-galactosidase RNA which acts as a tracer for injected gene expression, the uninjected side of the embryo acting as an internal control. Embryos were allowed to develop until the tailbud stage when they were fixed and stained for Xgal expression. Embryos in which injections had been correctly targeted to the dorsal head and neural tube regions were then subjected to in situ hybridization to detect several regional and general neural markers. Expression of the early regional 2-4) or 500 pg neuro D (lanes 5-7) RNA. These RNAs were either injected alone or in combination with 2 ng cdk5 WT RNA (lanes 3 and 6) or 2 ng cdk5 DN RNA (lanes 4 and 7). Animal caps were cut when embryos had reached stage 8.5 and aged until parallel embryos had reached stage 28. cDNAs were then prepared and quantitative RT-PCR analysis was used to detect expression of the neural markers NCAM and neural ␤-tubulin and the ubiquitous EF1␣, used as a loading control. (B) Embryos were left uninjected (lane 1) or injected with 50 pg neurogenin (lane 2) or 50 pg neurogenin with 2 ng cdk5 DN (lane 3). Animal caps were cut at stage 8.5 and then aged until parallel embryos had reached stage 28. Protein extracts were prepared, endogenous cdk5 was immunoprecipitated as described under Materials and Methods, and the immunoprecipitates were tested for their ability to phosphorylate the model substrate histone H1. neural markers Otx-2 [expressed in forebrain and midbrain (Pannese et al., 1995) ] and En 2 [expressed at midbrain/hind brain boundary (Brivanlou and Harland, 1989; HemmatiBrivanlou et al., 1991) ] was unaffected by expression of either WT or DN cdk5 (data not shown), indicating that cdk5 is not required for early anteroposterior patterning of the neural tube. Given that cdk5 kinase activity and enhanced expression of its activators only become apparent on neural differentiation in animal caps, we wished to determine whether blocking cdk5 kinase activity affected the expression pattern of a marker for terminal differentiation, neural ␤-tubulin. In agreement with animal cap experiments, expression of neural ␤-tubulin was largely unaffected in areas of the neural tube where cdk5 kinase activity was blocked by cdk5 DN expression (data not shown). However, the majority of embryos injected with cdk5 DN showed a substantial reduction in the size of the eye in the expressing area and infrequently nerves of the trigeminal ganglia were lost on the injected side (data not shown, but see Fig. 8 ).
To investigate this phenotype more closely, we injected embryos with 2.5 ng cdk5 WT or DN into the animal hemisphere of two dorsal cells of a four-cell embryo along with the lineage tracer ␤-galactosidase. These embryos were then stained for expression of Pax 6 and also with Xgal as a marker of the injected region. Pax 6 is a homeoboxcontaining transcription factor which has been shown to be intimately involved in eye development in the Xenopus tadpole and acts as a good marker for eye development even at early stages before these organs are fully formed (Hirsch and Harris, 1997) . Embryos overexpressing cdk5 WT developed normally compared to uninjected controls ( Fig. 8a) and had two large eyes staining strongly for Pax 6. In contrast, embryos injected with cdk5 DN were stunted along the anteroposterior axis as observed previously (Philpott et al., 1997) . In addition, these embryos showed significantly reduced eyes as determined by visual inspection and as delineated by Pax 6 staining. To demonstrate that this reduction in eye size was specific for blocking cdk5 kinase activity, we performed a rescue experiment where cdk5 WT RNA was injected along with cdk5 DN RNA. This combination largely rescued the eyes as judged by extent of Pax 6 staining ( Figs. 8a and 8b) , demonstrating the specificity of the small eye phenotype seen when cdk5 kinase activity is blocked. When embryos were injected into one cell of a two-cell embryo with cdk5 DN RNA, reduction of the eye was frequently seen but only on the injected side of the embryo (data not shown).
Cdk5 has been shown to associate with cyclin D1 (Xiong et al., 1992) . Although these complexes have not demonstrated H1 kinase activity, phosphorylation of unknown substrates cannot be ruled out. Cyclin D1 is expressed at high levels in the Xenopus eye (T. Hunt, personal communication) and it is possible that cyclin D1 and cdk5 do function together in eye formation. To test this possibility, we coexpressed Xenopus cyclin D1 (a generous gift of T. Hunt) along with cdk5 DN to see whether this would rescue the small eye phenotype that results from injection of cdk5 DN alone. We found that embryos injected with cyclin D1 along with cdk5 DN still had eyes of reduced size (data not shown). This failure to rescue the small eye phenotype seen when cdk5 kinase activity is blocked using the dominant negative construct indicates that its function in eye development is independent of any ability to interact with cyclin D1.
Cdk5 Dominant Negative Expression Gives Morphological Disruption of Eyes
We wished to determine whether embryos expressing cdk5 DN had correctly formed but merely reduced eyes or whether eye structure was disrupted, similar to the disruption seen in myotomal muscle when cdk5 kinase activity is blocked. Five nanograms of cdk5 WT and/or cdk5 DN were injected into two dorsal cells of a four-cell embryo which was allowed to develop until stage 35/36 and then fixed and sectioned to investigate eye morphology. Cdk5 WT-injected embryos showed normal, well-organized eyes which were indistinguishable from those in the uninjected embryo (Fig.  8biii) . In contrast, embryos expressing cdk5 DN showed eyes of reduced size which were substantially disrupted (Fig. 8bii) . Although the lens was present, it was smaller and often misshapen. Additionally, in cdk5 DN-injected embryos the retina appeared to be of normal thickness but edge to edge distance was reduced giving rise to a smaller eye. Strikingly, tissues of the retina did not display their usual sharp vitreal boundary but instead showed disorganization in these regions. This was consistently seen with cdk5 DN-expressing embryos and could be rescued by coinjection of cdk5 WT (see below) and thus cannot be accounted for by sectioning artifacts. Interestingly, this disruption of tissue boundaries is reminiscent of the effect of blocking cdk5 kinase activity in formation of myotomal muscle boundaries in the Xenopus embryo. In contrast to embryos where cdk5 kinase activity has been blocked, a majority of embryos which have been coinjected with cdk5 WT along with cdk5 DN, thus rescuing kinase activity, were of normal size and displayed the usual ordered and regular organization of both lens and retina. To confirm these observations we have quantitated the eye defects described here.
Between 10 and 12 eyes from each class of embryo were inspected carefully in all planes of section to determine the proportion that had formed normally. All eyes in the uninjected and cdk5 WT-injected embryos were normal. In contrast, of 11 eyes examined in cdk5 DN-expressing embryos, only 2 looked normal, 1 was mildly disrupted, while 8 showed more significant disruption (Fig. 8bii) . Four of these eyes were so substantially disrupted that little structure could be determined (not illustrated in Fig. 8bii ). Of 12 eyes sectioned in embryos which were expressing cdk5 WT and cdk5 DN together, 9 were entirely normal while the remaining 3 showed mild disruption (such as the top eye, Fig. 8biv ). This demonstrates that blocking cdk5 kinase activity specifically results in reduction and disruption of the embryonic eye and that normal eye structures can be rescued by restoration of cdk5 kinase activity.
In Fig. 7 , we demonstrate that cdk5 DN overexpression is unable to block induction of neural markers in animal caps. We have determined that noggin (but not neurogenin) is able to induce the expression of the eye markers Pax 6 and Rx (Casarosa et al., 1997; Hirsch and Harris, 1997; Mathers et al., 1997) in animal caps aged to stage 20 (data not shown). Overexpression of cdk5 DN (or cdk5 WT) does not affect the level of Pax 6 or Rx message induced in these animal caps in response to noggin. From these results we conclude that the role of cdk5 in eye development is not at the level of controlling the expression of genes which coordinate eye development.
We also attempted to investigate the effect of overexpression of Xp35.2. Overexpression of Xp35.2 even at modest levels (100 pg) causes cell death at the site of injection. Lower levels still result in either generalized disruption of embryonic tissue or have no effect (data not shown). However, as yet we have been unable to identify conditions where coinjection of cdk5 DN will rescue this phenotype (by blocking the activation of cdk5 kinase by the injected Xp35.2). Thus, we have been unable to determine whether the cell death and disruption we see on Xp35.2 overexpression are specific. Interestingly, a construct of Xp35.2 that codes for only the cdk5 binding and activation domain has little reproducible effect on embryonic development even at high levels (data not shown) indicating the functional importance of the N-terminal domain. The precise role of this region has yet to be elucidated.
DISCUSSION
Cdk5 has been demonstrated to have an important role in development and organization of the mammalian nervous system; a cdk5 null mouse shows perinatal lethality and displays severe disruption of specific regions in the brain (Ohshima et al., 1996) . It is difficult to determine whether these represent late patterning defects or whether they are a manifestation of a much earlier underlying problem in neural differentiation which appears later as defects in cortical layering and cerebellar foliation. To determine whether cdk5 functions in the earliest stages of neural differentiation and patterning, we have turned to embryos of the frog X. laevis which provide an excellent system to study the initial events of neural induction, differentiation, and patterning, both in the intact early embryo and in explant cultures.
Unexpectedly, compared to the neural-specific p35 and p39 mammalian genes so far identified, we cloned two classes of cdk activator from Xenopus embryos which show markedly differing expression patterns. Xp35.1 has been described previously (Philpott et al., 1997) and is found in both proliferating and differentiating nerve and muscle cells. In this report we describe a new activator of Xenopus cdk5, Xp35.2, which in contrast to Xp35.1 is expressed solely in differentiating neurons. The expression of mammalian p35 has been described in detail in older mouse and rat embryos in regions of the complex central nervous system of the developing mammalian embryo such as the cerebral cortex, midbrain, and hindbrain (Delalle et al., 1997; Zheng et al., 1998) . Using Xenopus embryos, we demonstrate that Xp35.2 expression is pronounced even at the earliest stage of neurogenesis, namely formation of the primary neurons which are the first neurons to differentiate in the embryonic neural plate and which control larval behavior (Hartenstein, 1989) . RT-PCR analysis demonstrates that overall Xp35.2 expression increases dramatically at stage 23. Jacobson and Huang (1985) have demonstrated that it is at about this time that pioneer neurons are growing out in the first neurite outgrowth in the embryo. Secondary neurite outgrowth in rostral regions is extensive between stages 24 and 30 when we demonstrate that Xp35.2 is strongly expressed by both RT-PCR and in whole-mount in situs. Indeed, clearing of the embryos reveals strong expression of Xp35.2 in all regions of the brain where extensive neurite outgrowth is occurring. Therefore, expression patterns indicate that the presence of Xp35.2 is tightly correlated with neural differentiation and possibly neurite outgrowth. This contrasts with Xp35.1 which is expressed in all cells competent to become neurons even while they are still proliferating. Cdk5 kinase activity does not seem to be regulated by phosphorylation like the other cdks (Poon et al., 1997) so levels of kinase activity may be largely determined by the expression of p35 activating subunits.
Molecular pathways resulting in neurogenesis in the early embryo have been investigated extensively using Xenopus embryos. We wished to establish whether induction of neural differentiation could lead to activation of cdk5 kinase. To this end, we injected neurogenin and neuro D into embryos. These neurogenic genes can induce the formation of terminally differentiated neurons with elaborated neurites in Xenopus animal caps, neuro D probably working downstream from neurogenin in the same pathway Ma et al., 1996) . We also injected noggin, an inhibitor of BMP signaling, which is believed to force cells down a default pathway of neural differentiation but which alone is unable to induce terminal neural differentiation (Ferreiro et al., 1994; Lamb et al., 1993; Papalopulu and Kintner, 1996) . All three of these neutralizers produce a robust expression of the neural marker NCAM in animal caps. However, only neurogenin and neuro D, but not noggin, were able to activate cdk5 kinase. It is interesting to note that in the whole embryo Xp35.1 is found over the entire expanse of the neural plate in both proliferating and differentiating cells, while the expression of Xp35.2 is tightly linked to regions of neural differentiation and neurite outgrowth. Neurogenin and neuro D which induce terminal neural differentiation in the animal cap assay upregulate the expression of Xp35.2 much more dramatically than Xp35.1 especially at later time points, indicating that the expression of Xp35.1 and Xp35.2 is regulated differently.
It has been reported that noggin alone is unable to induce the expression of markers of terminal neural differentiation (Ferreiro et al., 1994; Lamb et al., 1993; Papalopulu and Kintner, 1996) . In the experiment shown here, noggin injection is able to induce modest expression of the differentiation marker neural ␤-tubulin even by stage 13 (Fig. 6,  lane 4) , although the extent to which this is seen varies between experiments. This finding could represent subtle differences in experimental conditions between those used here and those of other groups (Ferreiro et al., 1994; Lamb et al., 1993) , e.g., noggin level, cap size, precise age at cap cutting, length of cap aging, and extreme sensitivity of detection by RT-PCR. In any case, noggin is unable to induce the expression of Xp35s, cdk5, or cdk5 kinase activity in the animal cap assay. This could reflect the inefficiency of noggin at producing differentiated neurons or could indicate that noggin and neurogenin/neuro D lie on two different pathways and cdk5 is only responsive to the pathway controlled by neurogenin. Indeed, even Xp35.1 that is expressed in proliferating neural precursors is not induced by noggin. It is possible that the lack of cdk5 kinase activity in animal caps reflects the more anterior nature of the neural tissue (Papalopulu and Kintner, 1996) induced by noggin. However, Xp35.1 is expressed in anterior and posterior neural tissue in the intact embryo (Philpott et al., 1997) , but it is still not induced in animal caps by noggin.
In a previous report (Philpott et al., 1997) we have demonstrated that cdk5 kinase, presumably partnered by Xp35.1, plays an unexpected role in regulating the expression of myogenic genes involved in muscle differentiation and consequently the expression of the muscle marker muscle actin. To determine whether cdk5 kinase activity was required for expression of early or late neural marker genes we injected cdk5 DN along with neurogenin or neuro D into early embryos. Blocking cdk5 kinase had no discernible effect on expression of NCAM or neural ␤-tubulin in animal caps (Fig. 7) . This is consistent with a role for cdk5/Xp35 complexes only in the cytoplasmic events of neurogenesis, for instance phosphorylation of cytoskeletal components to promote neurite outgrowth as is proposed in mammalian systems (Lew and Wang, 1995) . Indeed, both cdk5 and p35 null mice showed primarily disruption of neural tissue rather than an absence of neurons or an obvious failure in their ability to differentiate (Chae et al., 1997; Ohshima et al., 1996) . Moreover, cdk5 dominant negative does not affect expression of eye differentiation factors Pax 6 and Rx in animal caps in response to noggin (data not shown). This is in contrast to the role for cdk5 kinase in muscle differentiation in Xenopus which appears to act at least partly at the level of gene expression (Philpott et al., 1997) .
Dynamic growth and differentiation of neurons are essential to establish the complex organization of the mammalian brain. However, when loss of a gene such as cdk5 results in loss of organization of CNS structures in welldeveloped embryos it is difficult to determine at which stage the original neural defect arose. Again we have used the readily accessible embryos of the frog X. laevis to investigate the role of cdk5 kinase in formation of the central nervous system at the earliest embryonic stages. Embryos injected with cdk5 DN showed no obvious defects in expression of several neural markers, either regional (otx 2, En-2) or global (NCAM, all data not shown). Similarly, cdk5 DN did not block the expression of neural ␤-tubulin in the neural plate which is consistent with its inability to block neural differentiation in animal caps in response to neurogenin or neuro D. In some experiments, disruption of nerves emerging from the trigeminal ganglia was infrequently observed (data not shown) which may indicate some increased sensitivity of these tracts to loss of cdk5 kinase activity and, indeed, these tracts express high levels of Xp35.2 (Fig. 4) . While obvious defects of the neural tube were not observed, embryos in which cdk5 kinase activity had been blocked showed substantially reduced eyes, revealed even at early stages of eye formation by staining for Pax 6 expression (Fig. 8a) . These reduced eyes also show substantial tissue disorganization (Fig. 8b ) reminiscent of the disruption of myotomal muscle seen when cdk5 kinase activity is blocked in the early embryo.
Reduction in eye size can be a relatively common result of nonspecific perturbations in the early embryo, most of which lead to anterior truncations. However, for a number of reasons we believe that in this case it is a specific effect of blocking cdk5 kinase activity. First, cdk5 protein is highly expressed in the eye and Xp35.1 is expressed in the lens (Philpott et al., 1997) while Xp35.2 is expressed in differentiating retinal ganglion cells (Fig. 4) . These expression patterns indicate that cdk5 partnered by Xp35.1 and Xp35.2 is correctly placed to play a role in development of the eye. The mammalian homologues p35 and p39 are also found to be strongly expressed in the eye (Zheng et al., 1998 (Zheng et al., , 1998 Gao et al., 1997) . In addition, and most importantly, the reduced and disrupted eye phenotype produced by injecting cdk5 DN can be overcome by coexpression of cdk5 WT which restores cdk5 kinase activity. Such rescue would only be expected if eye reduction and disruption were a direct and specific result of blocking cdk5 kinase activity. Eyes form as outgrowths from the neural tube and may be reduced when there is an overall reduction in the size of the neural plate or neural tube. However, cdk5 DN injection resulted in no obvious reduction in the expanse of the neural plate at early stages as judged by NCAM staining (data not shown) making this explanation for reduced eye size unlikely. The reduction in eye size that we observe here is consistent with a block in division of the retinal primordial cells in the early tailbud-stage embryo, although such a relationship has not been directly demonstrated. It is unlikely that cdk5 is functioning to titrate cyclin D1 away from its normal activating kinase (cdk4 or cdk6) during eye development. If this were the case, overexpression of both wild-type and dominant negative cdk5 would be expected to produce embryos with reduced eyes. Moreover, an active role for cyclin D1-cdk5 complexes is unlikely as overexpression of Xenopus cyclin D1 is unable to rescue the small eye phenotype produced by overexpression of cdk5 DN (data not shown).
The expression pattern of Xp35s in differentiating neurons coupled with the experimental work in Xenopus and mammalian systems indicates that cdk5/p35s function widely in neural differentiation in the central nervous system (CNS), yet there are no obvious defects in patterning or formation of the neural tube in the early Xenopus embryo. Cdk5/Xp35 may not be essential for neural differentiation in the neural tube at these early stages or other pathways may compensate for a loss of cdk5 kinase activity in the brain and spinal cord (but not in the eye). Alternatively, residual cdk5 kinase activity found even in the presence of cdk5 DN may be enough to allow normal differentiation, patterning, or neurite outgrowth in the neural tube while the eye may be particularly sensitive to cdk5 kinase loss. Given the pleiotropic effects of loss of cdk5 in the null mouse compared to the limited pleitropy we see in the frog CNS at these early developmental stages, it seems likely that other requirements for cdk5 in development of the CNS would become apparent in the frog either if cdk5 kinase activity could be blocked completely or if more complex aspects of central nervous system development in the older organism were investigated. The mouse is a good model for studying the later requirements for cdk5 in development of CNS structures, for instance, in cortical layering. The structure of the eye in cdk5 null mice has not been reported.
The ubiquitous expression of cdk5 and the identification of two cdk5 activators in frog with quite different expression patterns indicate a potentially broad role for cdk5 kinase in development of a range of tissues even at early stages of organization and patterning. It will be interesting to determine whether more p35 homologues will be identified which may function in the differentiation and patterning of other embryonic tissues.
